trimetazidine has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hang, WJ; Peng, YZ; Shen, L; Shu, HY; Wang, DW; Zhang, M; Zhou, N | 1 |
| Fu, M; Hao, K; Li, S; Liu, Y; Yang, Q; Yang, X; Zhou, Z | 1 |
2 other study(ies) available for trimetazidine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Trimetazidine enhances myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice through directly activating Akt and promoting the binding of HSF1 to VEGF-A promoter.
Topics: Angiogenesis Inducing Agents; Animals; Cardiomegaly; Heat Shock Transcription Factors; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Myocardium; Myocytes, Cardiac; Neovascularization, Pathologic; Norepinephrine; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Transcription Factors; Trimetazidine; Vascular Endothelial Growth Factor A | 2022 |
Trimetazidine mitigates high glucose-induced retinal endothelial dysfunction by inhibiting PI3K/Akt/mTOR pathway-mediated autophagy.
Topics: Autophagy; Cell Proliferation; Endothelial Cells; Glucose; Humans; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Trimetazidine | 2022 |